Follow Us on Google News
WASHINGTON: The US Food and Drug Administration has authorized second pill to treat COVID-19, adding another at-home treatment option to help keep high-risk people out of the hospital.
This is the second Covid-19 antiviral pill authorized for ill people to take at home, before they get sick enough to be hospitalized. Merck has an agreement with the US government for the company to supply 3.1 million courses of molnupiravir upon this authorization.
The Food and Drug Administration (FDA) said Merck & Co’s antiviral pill, which is designed to introduce errors into the genetic code of the virus, could be used when other authorised treatments are not accessible or clinically appropriate.
The drug, molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalisations and deaths by around 30 per cent in a clinical trial of high-risk individuals early in the course of the illness.
The authorisation allows the use of the drug for mild-to-moderate Covid-19 and along with the Pfizer pill, it could be an important tool against the fast-spreading Omicron variant.
Pfizer’s drug, Paxlovid, was authorised on Wednesday for people aged 12 and older and has shown to be nearly 90pc effective in preventing hospitalisations and deaths in patients at high risk of severe illness, according to trial data.
The FDA says some patients should avoid Pfizer two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.
Merck plans to ship hundreds of thousands of treatment courses in coming days and one million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.
The FDA has authorised intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.
Merck said that its treatment had advantages over the Pfizer pill. “It doesn’t require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,” Nick Kartsonis, Merck’s senior vice president of clinical research for vaccines and infectious diseases, told Reuters.
Merck’s drug is not authorised for use in patients younger than 18 because molnupiravir may affect bone and cartilage growth, the FDA said. The pill is not recommended for use during pregnancy, the agency added.
The drug is meant to be taken twice a day — four pills each time — for five days, making a full treatment course of 40 pills. The treatment was priced at about $700 per course in a deal with the US government for up to 5m courses.
